Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

FDA scrutiny on nitrosamine impurities continues to shape GMP expectations. This article explains acceptable intake calculation, NDMA and NDEA limits, and how manufacturers align documentation with FDA nitrosamine risk assessment requirements to reduce inspection exposure and strengthen compliance readiness
EMA nitrosamine Appendix 1 has reshaped how inspectors assess risk, justification, and lifecycle oversight. This article explains what regulators review during GMP inspections, how expectations apply in practice, and why governance gaps often escalate nitrosamine-related findings.
This article explains how impurity formation risks emerge during pharmaceutical manufacturing and why GMP inspectors focus on formation logic, traceable decisions, and lifecycle controls. It provides an inspection-oriented view of regulatory expectations and common quality system gaps.
Nitrosamine oversight has become a critical focus for regulators worldwide. This article explains how inspection expectations, pharmacovigilance governance, and evidence traceability shape regulatory decisions and long-term compliance strategies across pharmaceutical product lifecycles.
The regulation of nitrosamine impurities has been evolving rapidly due to concerns about their potential health risks, particularly their carcinogenicity. Regulatory authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Therapeutic Goods
The detection of N-nitrosamine impurities in medicines and the increasing presence of nitrosamine drug substance-related impurities (NDSRIs) have presented significant challenges for both drug manufacturers and regulatory agencies.
The CPCA for Nitrosamine simplifies the complex process of assessing nitrosamine impurities by categorizing them based on carcinogenic risk.
Artificial intelligence is revolutionizing how pharmaceutical companies predict and mitigate nitrosamine risks. From early-stage risk assessments to real-time monitoring and regulatory compliance, AI offers precision and efficiency.
Comprehensive information about the API’s chemical structure, properties, and synthesis process is crucial for identifying potential nitrosamine contamination sources.
The Nitrosamine Risk Assessment Questionnaire for Drug Products is a critical tool used by pharmaceutical manufacturers to evaluate and mitigate the risk of nitrosamine contamination in their products.